Chlorothiazide
API’s Name：Chlorothiazide
CAS No.：58-94-6
Indication：Diuretics
Innovator：
Specification：USP/EP
US DMF：
EU DMF：
CEP：
Only for R&D purpose
Intermediates
Product Detail
Background
Chlorothiazide is an inhibitor of carbonic anhydrase and is slightly less potent than acetazolamide. This compound has been shown to block reabsorption of sodium and chloride ions.
Description
Chlorothiazide is a diuretic and antihypertensive. (IC50=3.8 mM) Target: Others Chlorothiazide sodium (Diuril) is a diuretic used within the hospital setting or for personal use to manage excess fluid associated with congestive heart failure. It is also used as an antihypertensive. Most often taken in pill form, it is usually taken orally once or twice a day. In the ICU setting, chlorothiazide is given to diurese a patient in addition to furosemide (Lasix). Working in a separate mechanism than furosemide, and absorbed enterically as a reconstituted suspension administered through a nasogastric tube (NG tube), the two drugs potentiate one another.
Clinical Trial
NCT Number | Sponsor | Condition | Start Date | Phase |
NCT03574857 | University of Virginia | Heart Failure|Heart Failure With Reduced Ejection Fraction|Heart Failure Acute|Cardiovascular Diseases | June 2018 | Phase 4 |
NCT02546583 | Yale University|National Heart, Lung, and Blood Institute (NHLBI) | Heart Failure | August 2015 | Not Applicable |
NCT02606253 | Vanderbilt University|Vanderbilt University Medical Center | Heart Failure | February 2016 | Phase 4 |
NCT00004360 | National Center for Research Resources (NCRR)|Northwestern University|Office of Rare Diseases (ORD) | Diabetes Insipidus, Nephrogenic | September 1995 | |
NCT00000484 | National Heart, Lung, and Blood Institute (NHLBI) | Cardiovascular Diseases|Heart Diseases|Hypertension|Vascular Diseases | April 1966 | Phase 3 |
Chemical structure
